|
Emergence of pristinamycin resistance in India
Shyam Sunder Keshari1, Arun Kumar Kapoor1, Nira Kastury1, Dharmendra Kumar Singh2, Anudita Bhargava1
1 Department of Pharmacology and Microbiology, Moti Lal Nehru Medical College, Allahabad, Uttar Pradesh, India
2 Department of Pediatrics, Sarojini Naidu Children Hospital, Allahabad, Uttar Pradesh, India
Correspondence Address:
Arun Kumar Kapoor
Department of Pharmacology and Microbiology, Moti Lal Nehru Medical College, Allahabad, Uttar Pradesh
India
Quinupristin and dalfopristin combination has been advocated as a drug of choice for multi-drug resistant (MDR) gram-positive cocci (GPC). We are reporting two cases of neonatal septicemia, caused by the methicillin resistant Staphylococcus aureus (MRSA), showing primary in vitro pristinamycin resistance. The Minimum inhibitory concentrations (MIC) for pristinamycin in these two cases were 30 µg and 25 µg, respectively. Universal advocacy of pristinamycin for the therapy of MDR GPC infections should be re-evaluated.
How to cite this article:
Keshari SS, Kapoor AK, Kastury N, Singh DK, Bhargava A. Emergence of pristinamycin resistance in India.Indian J Pharmacol 2009;41:47-48
|
How to cite this URL:
Keshari SS, Kapoor AK, Kastury N, Singh DK, Bhargava A. Emergence of pristinamycin resistance in India. Indian J Pharmacol [serial online] 2009 [cited 2021 Feb 25 ];41:47-48
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2009;volume=41;issue=1;spage=47;epage=48;aulast=Keshari;type=0 |
|
